DICE Therapeutics Statistics Share Statistics DICE Therapeutics has 47.76M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 47.76M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) n/a Shares Floating n/a Failed to Deliver (FTD) Shares 50,004 FTD / Avg. Volume 2.85%
Short Selling Information The latest short interest is 4.36M, so 9.13% of the outstanding
shares have been sold short.
Short Interest 4.36M Short % of Shares Out 9.13% Short % of Float 14.6% Short Ratio (days to cover) 5.2
Valuation Ratios The PE ratio is -15.05 and the forward
PE ratio is null.
DICE Therapeutics's PEG ratio is
0.32.
PE Ratio -15.05 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio -6.55 P/FCF Ratio -18.47 PEG Ratio 0.32
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for DICE Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 38.14,
with a Debt / Equity ratio of -0.07.
Current Ratio 38.14 Quick Ratio 38.14 Debt / Equity -0.07 Debt / EBITDA -0.16 Debt / FCF -0.2 Interest Coverage -129.93
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.15M Employee Count 71 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -2.22M Effective Tax Rate 2.65%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0, so DICE Therapeutics's
price volatility has been lower than the market average.
Beta 0 52-Week Price Change n/a 50-Day Moving Average 45.12 200-Day Moving Average 34.83 Relative Strength Index (RSI) 77.58 Average Volume (20 Days) 1,753,229
Income Statement
Revenue n/a Gross Profit n/a Operating Income -88.22M Net Income -81.66M EBITDA -83.01M EBIT -83.21M Earnings Per Share (EPS) -2.07
Full Income Statement Balance Sheet The company has 461.39M in cash and 13.27M in
debt, giving a net cash position of 448.13M.
Cash & Cash Equivalents 461.39M Total Debt 13.27M Net Cash 448.13M Retained Earnings -187.59M Total Assets 550.67M Working Capital 511.73M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -64.32M
and capital expenditures -2.24M, giving a free cash flow of -66.56M.
Operating Cash Flow -64.32M Capital Expenditures -2.24M Free Cash Flow -66.56M FCF Per Share -1.69
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
